Search

Displaying results 701 - 710 of 7067 in total
  1. Drug

    Oxybenzone

    go.drugbank.com/drugs/DB01428
    Approved

    It is used as an ingredient in sunscreen and other cosmetics because it absorbs UV-A ultraviolet rays. … It is a derivative of benzophenone. It forms colorless crystals that are readily soluble in most organic solvents.

    Mixtures: Blistex European Formula, A M Stimulus Complex SPF 25Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    It is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Reslizumab is marketed as Cinqaero in Europe. … the first attack compared to patients receiving placebo [FDA Label, A31579].

  3. Drug

    Pheniramine

    go.drugbank.com/drugs/DB01620
    Approved

    Pheniramine is a first-generation antihistamine in the alkylamine class, similar to [brompheniramine] and [chlorpheniramine].

    Mixtures: Alahist D, Rhume Et De LA Grippe (extra-fort)
  4. Drug

    Sodium molybdate

    go.drugbank.com/drugs/DB14496
    Approved

    Mixtures: Complex, One-A-day Advance Men's
  5. Drug

    Lanolin

    go.drugbank.com/drugs/DB11112
    Approved

    Lanolin is a yellow fat obtained from sheep's wool. It is used as an emollient, cosmetic, and pharmaceutic aid [L2580].

    Mixtures: Blistex European Formula, Dg Baby Vitamins A and DCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. … Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.

  7. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia.[L39030] This indication is valid in the US, Europe, and Canada. … L10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index
  8. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO. … Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology

  9. Drug

    Dihydrocodeine

    go.drugbank.com/drugs/DB01551
    ApprovedIllicit

    It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis

    Mixtures: Duohist DH, EndaCof DHInternational brands: DF-118 Forte
  10. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    [A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and … In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults.